Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1996-12-10
2009-10-20
Ewoldt, G. R (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C530S328000
Reexamination Certificate
active
07604811
ABSTRACT:
This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.
REFERENCES:
patent: 3540444 (1970-11-01), Moreland
patent: 3773919 (1973-11-01), Boswell
patent: 3788315 (1974-01-01), Laurens
patent: 4166800 (1979-09-01), Fong
patent: 4384975 (1983-05-01), Fong
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4622244 (1986-11-01), Lapka et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4675189 (1987-06-01), Kent et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4941880 (1990-07-01), Burns
patent: 5000886 (1991-03-01), Lawter et al.
patent: 5019096 (1991-05-01), Fox, Jr. et al.
patent: 5059187 (1991-10-01), Sperry et al.
patent: 5064413 (1991-11-01), McKinnon et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5129825 (1992-07-01), Discko, Jr.
patent: 5133701 (1992-07-01), Han
patent: 5236355 (1993-08-01), Brizzolara et al.
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5290494 (1994-03-01), Coombes et al.
patent: 5360610 (1994-11-01), Tice et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5429822 (1995-07-01), Gresser et al.
patent: 5500228 (1996-03-01), Lawter et al.
patent: 5538739 (1996-07-01), Bodmer et al.
patent: 5639480 (1997-06-01), Bodmer et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648096 (1997-07-01), Gander et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5688530 (1997-11-01), Bodmer et al.
patent: 5693343 (1997-12-01), Reid et al.
patent: 5762965 (1998-06-01), Burnett et al.
patent: 5811128 (1998-09-01), Tice et al.
patent: 5814344 (1998-09-01), Tice et al.
patent: 5820883 (1998-10-01), Tice et al.
patent: 5853763 (1998-12-01), Tice et al.
patent: 0052510 (1994-10-01), None
patent: WO 92/19263 (1992-11-01), None
Cassels, F.J., et al. J. Ind. Microbiol. 1995;15:214-226.
Cassels, F.J., et al. Infec. Immun. Jun. 1992;60(6):2174-2181.
Evans, D. G. et al., Infect. lmmun. 25:738-748, “Purification and characterization of the CFA/I antigen of enterotoxicEsherichia coli”, Aug. 1979.
Hall, R. H. et al., J. Bacteriol. 171:6372-74, “Purification and analysis of colonization factor antigen I, coli surace antigen I and coli surfac antigen 3 fimbriae from enterotoxigenicEscherichia coli”, Nov. 1989.
Karjalainen, T. K. et al., Infect. Immun. 57:1126-1130, “Molecular cloning of nucleotide sequence of the colonization factor antigen I gene ofEscherichia coli”, Apr. 1989.
Edelman, et al., Immunization of rabbits with enterotoxigenicE. colicolonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide), Vaccine, vol. 11, Issue 2, p. 155-158, (1993).
Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp. 1459-1464.
Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.
Hall, et al., Purification and Analysis of Colonization Factor Antigen I, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriae from EnterotoxigenicEscherichia coli, Journal of Bacteriology, Nov. 1989, p. 6372-6374, vol. 171, No. 11.
Evans, et al. Purification and Characterization of the CFR/I Antigen of EnterotoxigenicEscherichia coli, Infection and Immunity, Aug. 1979, p. 738-748, vol. 25.
Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene ofEscherichia coli, Infection and Immunity, Apr. 1989, p. 1126-1130, vol. 57.
Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres for Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p. 351-352/.
Yeh, A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445.
Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.
Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.
Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.
Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound Infection Control, Chemical Abstracts, 1983, pp. 215-226.
Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pill of Human EnterotoxigenicEscherichia coli, Infection and Immunity, Nov. 1990, p. 3594-3600, vol. 58, No. 11.
Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenicEscherichia coliof serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p. 265-270.
Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).
McConnel, et al., Antigenic homology within human enterotoxigenicEsherichia colifimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.
Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.
Cassels, et al., Analysis ofEscherichia coliColonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.
Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.
Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.
Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).
Brown, A hypothetical model of the foreign antigen biinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p. 845-850.
Boedeker Edgar C.
Cassels Frederick J.
Jarboe Daniel L.
Reid Robert H.
Arwine Elizabeth
Ewoldt G. R
The United States of America as represented by the Secretary of
LandOfFree
Oral-intestinal vaccines against diseases caused by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral-intestinal vaccines against diseases caused by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral-intestinal vaccines against diseases caused by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106003